Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5918492 | 0.89 | RIPK1 (0.46) | RIPK1AOC3 | |
| SCHEMBL16520314 | 0.82 | ADRB2 (0.42) | ADRB2SLC6A2SLC6A3SLC6A4TSHR | |
| SCHEMBL13893479 | 0.81 | ADRB2 (0.45) | ADRB2SLC6A2SLC6A3SLC6A4TSHR | |
| SCHEMBL15854207 | 0.78 | ESR1 (0.55) | SLC6A2SLC6A3SLC6A4TSHRHIF1A | |
| SCHEMBL28429831 | 0.78 | RIPK1 (0.39) | LMNAHPGDRIPK1HTR2AMEN1 | |
| SCHEMBL8373596 | 0.78 | ESR1 (0.55) | SLC6A2SLC6A3SLC6A4TSHRHIF1A | |
| SCHEMBL5664123 | 0.77 | RIPK1 (0.63) | SLC6A3SLC6A4TDP1RIPK1HTR2A | |
| SCHEMBL10077436 | 0.77 | SLC6A4 (0.43) | ADRB2SLC6A2SLC6A3SLC6A4TSHR | |
| SCHEMBL20993317 | 0.77 | ADRB2 (0.50) | ADRB2SLC6A2SLC6A3SLC6A4TSHR | |
| SCHEMBL22877735 | 0.77 | AOC3 (0.52) | ADRB2SLC6A2SLC6A3SLC6A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210186970-A1 | SELECTIVE CALCIUM CHANNEL ANTAGONISTS | NORTHWESTERN UNIVERSITY | 2021-06-24 | — | — | US | disclosed |
| US-20190167685-A1 | SELECTIVE CALCIUM CHANNEL ANTAGONISTS | NORTHWESTERN UNIVERSITY | 2019-06-06 | — | — | US | disclosed |
| US-20160310491-A1 | SELECTIVE CALCIUM CHANNEL ANTAGONISTS | NORTHWESTERN UNIVERSITY | 2016-10-27 | — | — | US | disclosed |
| US-9428467-B2 | Selective calcium channel antagonists | NORTHWESTERN UNIVERSITY (US) | 2016-08-30 | — | — | US | disclosed |
| US-20130116169-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-05-09 | — | — | US | disclosed |
| US-20120196883-A1 | SELECTIVE CALCIUM CHANNEL ANTAGONISTS | NORTHWESTERN UNIVERSITY | 2012-08-02 | — | — | US | disclosed |
| US-20120014914-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190167685-A1 | SELECTIVE CALCIUM CHANNEL ANTAGONISTS | CACNA1C, CACNA1B, CACNA1G | ADRB2 808/4885SLC6A2 372/4885SLC6A3 203/4885 |
| US-20160310491-A1 | SELECTIVE CALCIUM CHANNEL ANTAGONISTS | CACNA1C, CACNA1B, CACNA1G | ADRB2 808/4885SLC6A2 372/4885SLC6A3 203/4885 |
| US-20120014914-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASES | PRSS1, SERPINB1, SPINT2 | ADRB2 4801/4885SLC6A2 1308/4885SLC6A3 1202/4885 |
| US-20130116169-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | SERPINB1, PRSS1, SPINT2 | ADRB2 4846/4885SLC6A2 2823/4885SLC6A3 2679/4885 |
| US-20120196883-A1 | SELECTIVE CALCIUM CHANNEL ANTAGONISTS | CACNA1C, CACNA1B, CACNA1G | ADRB2 808/4885SLC6A2 372/4885SLC6A3 203/4885 |
| US-20210186970-A1 | SELECTIVE CALCIUM CHANNEL ANTAGONISTS | CACNA1C, CACNA1B, CACNA1G | ADRB2 808/4885SLC6A2 372/4885SLC6A3 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.